Supplimentary_Figure1-14 and Table 1-2 from Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma

Abstract

<p>Supplementary Figure 1. Activation of the CDK4/6 axis in human intrahepatic cholangiocarcinoma (ICC) specimens. Supplementary Figure 2. Levels of Rb1, CDK4, CDK6, E2F1, and Cyclin E1 mRNA in human intrahepatic cholangiocarcinoma (ICC) from The Cancer Genome Atlas (TCGA) and National Cancer Institute (NCI) datasets. Supplementary Figure 3: Effect of Palbociclib on ICC cell growth. Supplementary Figure 4: Effect of Palbociclib on the levels of putative target proteins in human ICC cell lines. Supplementary Figure 5. Inhibition of CyclinD1 (CCND1) expression enhances tumor cell growth suppressor capacity of Palbobiclib. Supplementary Figure 6. Correlation analysis of Retinoblastoma (Rb) expression and the growth inhibitory effects of Palbociclib. Supplementary Figure 7. Palbociclib inhibits proliferation of ICC cell lines in colony formation assays. Supplementary Figure 8. Retinoblastoma-dependent cell growth inhibition effect of long-term Palbociclib treatment in ICC cells. Supplementary Figure 9. Effect of combined Palbociclib/MLN0128 treatment on cell proliferation. Supplementary Figure 10. Synergistic effect of Palbociclib/MLN0128 combination in ICC cell lines. Supplementary Figure 11. Effect of combined Palbociclib/MLN0128 administration on cell cycle of ICC cell lines. Supplementary Figure 12. Effect of Palbociclib/MLN0128 on putative target proteins in intrahepatic cholangiocarcinoma (ICC) cell lines. Supplementary Figure 13. Overview of the apoptosis rate in ICC lesions from AKT/YapS127A mice subjected to the various treatment regimens. Supplementary Figure 14. Effect of Palbociclib/MLN0128 treatment on putative target proteins in AKT/YapS127A mice. Supplementary Table 1: Clinicopathological features of intrahepatic cholangiocarcinoma (ICC) patients Supplementary Table 2: Western blotting antibody information</p>